For Healthcare Professionals Outside the US
For Healthcare Professionals Outside the US
~40% of HR+/HER2- aBC patients have a PIK3CA mutation, and can have endocrine resistance and/or shorter mPFS2-5
Test at initial MBC
diagnosis9:
Test for PIK3CA mutations at initial MBC diagnosis if tumor is HR+/HER2-
PIK3CA mutations can be detected in tissue (using archival specimens and recent or new biopsies) or plasma. If mutation is not detected in plasma, test tumor tissue2